JPL Wealth Management LLC Purchases New Position in GSK plc (NYSE:GSK)

JPL Wealth Management LLC acquired a new position in GSK plc (NYSE:GSK) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 30,461 shares of the pharmaceutical company’s stock, valued at approximately $1,129,000.

A number of other large investors have also recently made changes to their positions in GSK. Caprock Group LLC boosted its stake in shares of GSK by 2.8% during the 4th quarter. Caprock Group LLC now owns 11,513 shares of the pharmaceutical company’s stock valued at $430,000 after purchasing an additional 317 shares in the last quarter. Horizon Bancorp Inc. IN boosted its holdings in shares of GSK by 8.9% during the 4th quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock valued at $147,000 after buying an additional 323 shares in the last quarter. MONECO Advisors LLC grew its position in shares of GSK by 2.9% in the 4th quarter. MONECO Advisors LLC now owns 12,433 shares of the pharmaceutical company’s stock worth $461,000 after buying an additional 346 shares during the period. AdvisorNet Financial Inc boosted its stake in GSK by 1.9% during the fourth quarter. AdvisorNet Financial Inc now owns 20,729 shares of the pharmaceutical company’s stock worth $768,000 after acquiring an additional 377 shares in the last quarter. Finally, Addison Advisors LLC grew its holdings in GSK by 11.9% in the fourth quarter. Addison Advisors LLC now owns 3,702 shares of the pharmaceutical company’s stock worth $137,000 after purchasing an additional 395 shares during the period. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GSK has been the topic of a number of analyst reports. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Citigroup raised GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Finally, Morgan Stanley started coverage on shares of GSK in a research note on Tuesday, January 23rd. They set an “equal weight” rating for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

GSK Stock Performance

Shares of NYSE:GSK traded up $1.09 during midday trading on Wednesday, reaching $45.55. 4,061,189 shares of the company’s stock traded hands, compared to its average volume of 3,504,651. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.58 and a current ratio of 0.87. GSK plc has a one year low of $33.33 and a one year high of $45.92. The company has a market cap of $94.40 billion, a price-to-earnings ratio of 16.11, a P/E/G ratio of 1.91 and a beta of 0.65. The stock has a 50 day moving average of $42.38 and a 200 day moving average of $39.98.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. The business had revenue of $9.34 billion during the quarter, compared to analyst estimates of $8.98 billion. GSK had a return on equity of 51.54% and a net margin of 14.62%. As a group, equities research analysts anticipate that GSK plc will post 4.1 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be issued a $0.3762 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $1.50 annualized dividend and a yield of 3.30%. This is a boost from GSK’s previous quarterly dividend of $0.36. GSK’s dividend payout ratio (DPR) is currently 53.26%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.